Enwei Pharmaceutical Co

Enwei Pharmaceutical Co OCF Margin

The Operating Cash Flow Margin of Enwei Pharmaceutical Co (301331.SZ) as of Oct 22, 2026 is 12.17 %. In the previous year, Operating Cash Flow Margin was 9.72 % — a change of 25.20% (higher).

OCF Margin

12.17 %

YoY

25.20%

Last updated:

Operating Cash Flow Margin of Enwei Pharmaceutical Co is 2025 12.17 % . Operating Cash Flow Margin of Enwei Pharmaceutical Co was 2024 9.72 % . It decreases by 25.20% higher compared to the previous year.

The Enwei Pharmaceutical Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
19.29 CNY
Jan 1, 2020
12.38 CNY
Jan 1, 2021
12.88 CNY
Jan 1, 2022
9.02 CNY
Jan 1, 2023
10.70 CNY
Jan 1, 2024
9.72 CNY
Jan 1, 2025
12.17 CNY
The Enwei Pharmaceutical Co OCF Margin history
YEAROCF MarginYoY
12.17 %+25.20%
9.72 %-9.18%
10.70 %+18.67%
9.02 %-30.02%
12.88 %+4.06%
12.38 %-35.80%
19.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enwei Pharmaceutical Co Stock analysis

What does Enwei Pharmaceutical Co do? Enwei Pharmaceutical Co., Ltd. generates revenue through the research, development, production, and sales of proprietary Chinese and chemical medicines. The company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules, and Danxiong Tongmai granules, which are primarily sold via direct sales and e-commerce channels. Its focus on gynecological products, pediatric medicines, and respiratory medicines targets domestic consumers seeking specialized healthcare solutions. The firm's domestic market strategy emphasizes direct customer engagement and online sales to reach its target segments. The company's product portfolio is tailored to specific health needs, with Jieeryin products addressing gynecological concerns, Shanmai Jianpi oral liquid supporting digestive health, Qingjing capsules for gynecological treatments, and Danxiong Tongmai granules targeting cardiovascular health. These offerings are distributed through direct sales teams and e-commerce platforms, aligning with the domestic market's preference for accessible healthcare products. Enwei's domestic focus ensures that its products meet local regulatory standards and consumer demands. Enwei Pharmaceutical's revenue streams are driven by the consistent demand for its specialized medicine categories, particularly in gynecology, pediatrics, and respiratory care. The firm's domestic market presence allows it to build strong relationships with healthcare providers and end-users, facilitating repeat purchases and brand loyalty. By concentrating on these key therapeutic areas, Enwei effectively serves its core customer segments without expanding into international markets. Enwei Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enwei Pharmaceutical Co stock

Operating Cash Flow Margin of Enwei Pharmaceutical Co is 12.17 % in 2025.

Operating Cash Flow Margin of Enwei Pharmaceutical Co changed from 9.72 % to 12.17 %, representing a 25.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Enwei Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Enwei Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Enwei Pharmaceutical Co

All Key Metrics — Enwei Pharmaceutical Co